Passage Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Passage Bio Reports First Quarter 2022 Financial Results And Provides Recent Business Highlights
Passage Bio Inc expected to post a loss of 89 cents a share - Earnings Preview
Passage Bio Inc expected to post a loss of 89 cents a share - Earnings Preview
Passage Bio Inc expected to post a loss of 89 cents a share - Earnings Preview
Brief: Passage Bio Announces Publication Of Preclinical Data That Support Ongoing Clinical Study Of Pbkr03 In Krabbe Disease
PassageBio jumps on extending cash runway, job cuts
Brief: Passage Bio Provides Update On Strategic Priorities, Extends Cash Runway
Brief: Passage Bio Inc Says On March 7, Liam Ratcliffe Notified Co Of His Decision To Resign From Board
Brief: Passage Bio Doses First Patient In Global Clinical Trial For Infantile Krabbe Disease, A Rare Fatal Pediatric Condition
U.S. RESEARCH ROUNDUP- Cara Therapeutics, DT Midstream, Fulcrum Therapeutics
Passage Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Passage Bio Reports Fourth Quarter And Full-Year 2021 Financial Results
Passage Bio Inc expected to post a loss of 89 cents a share - Earnings Preview
Passage Bio Inc expected to post a loss of 89 cents a share - Earnings Preview
Brief: Passage Bio To Showcase GM1 Gangliosidosis And Krabbe Clinical Programs
U.S. RESEARCH ROUNDUP- Exxon Mobil, JP Morgan, Wells Fargo & Co
Brief: Passage Bio Inc - Cash On Hand To Fund Operations To Year-End 2023
Brief: Passage Bio Announces Positive Interim Data And Advances Phase 1/2 Trial Of Pbgm01 In Gm1 Gangliosidosis